Abstract Library

#3103 Comparison of 18F-DOPA versus 68Ga-DOTA-TOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms

Introduction: 18F-DOPA and 68Ga-DOTA-TOC are two diagnostic PET tracers used in neuroendocrine neoplasms (NENs). As both tracers utilise different metabolic pathways, lesion detection results often show disparities, but comparative studies are lacking.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Veenstra E

Authors: Veenstra E, de Groot D, Brouwers A, Walenkamp A, Noordzij W,

Keywords: neuroendocrine tumor, PET, tracer, 18F-DOPA, 68GA-DOTA-TOC, tumor marker, carbidopa,

#2089 Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs

Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Virgolini I, Brouwers A, Haug A, Grønbæk H, Kjær A,

Keywords: 68Ga-OPS202, GEP-NET, SSTR2, optimal dose range,

#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment

Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Brouwers A, Van Asselt S, Oosting S, De Jong J, Lub-de Hooge M,

Keywords: neuroendocrine tumors, 89Zr-bevacizumab PET, VEGF-A, everolimus, biomarker,